About Enliven Therapeutics, Inc.
https://www.enliventherapeutics.comEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
CEO
Samuel S. Kintz
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-02-24 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:7.96M
Value:$207.35M
FMR LLC
Shares:7.13M
Value:$185.72M
COMMODORE CAPITAL LP
Shares:4.69M
Value:$122.25M
Summary
Showing Top 3 of 144
About Enliven Therapeutics, Inc.
https://www.enliventherapeutics.comEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $25.1M ▼ | $-20.15M ▲ | 0% | $-0.32 ▲ | $-20.09M ▲ |
| Q2-2025 | $0 | $28.58M ▼ | $-25.34M ▲ | 0% | $-0.49 ▲ | $-28.5M ▲ |
| Q1-2025 | $0 | $31.69M ▲ | $-28.54M ▼ | 0% | $-0.57 ▼ | $-31.62M ▼ |
| Q4-2024 | $0 | $26.9M ▼ | $-23.18M ▼ | 0% | $-0.46 ▲ | $-26.82M ▲ |
| Q3-2024 | $0 | $27.07M | $-23.16M | 0% | $-0.48 | $-26.99M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $477.56M ▼ | $490.88M ▼ | $14.75M ▼ | $476.12M ▼ |
| Q2-2025 | $490.5M ▲ | $503.89M ▲ | $15.41M ▲ | $488.47M ▲ |
| Q1-2025 | $289.56M ▼ | $302.57M ▼ | $14.27M ▼ | $288.3M ▼ |
| Q4-2024 | $313.44M ▲ | $325.76M ▲ | $15.91M ▼ | $309.85M ▲ |
| Q3-2024 | $291.83M | $305.43M | $17.03M | $288.4M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-20.15M ▲ | $-13.28M ▲ | $-4.06M ▲ | $-368K ▼ | $-17.7M ▼ | $-13.28M ▲ |
| Q2-2025 | $-25.34M ▲ | $-17.06M ▲ | $-183.59M ▼ | $218.38M ▲ | $17.73M ▲ | $-17.2M ▲ |
| Q1-2025 | $-28.54M ▼ | $-24.13M ▼ | $1.43M ▲ | $234K ▼ | $-22.47M ▼ | $-24.15M ▼ |
| Q4-2024 | $-23.18M ▼ | $-17.2M ▼ | $727K ▼ | $39.97M ▲ | $23.5M ▲ | $-17.2M ▼ |
| Q3-2024 | $-23.16M | $-12.19M | $14.83M | $1.12M | $3.75M | $-12.21M |
CEO
Samuel S. Kintz
Compensation Summary
(Year 2023)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-02-24 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 114
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:7.96M
Value:$207.35M
FMR LLC
Shares:7.13M
Value:$185.72M
COMMODORE CAPITAL LP
Shares:4.69M
Value:$122.25M
Summary
Showing Top 3 of 144